Naxitamab

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** A humanized monoclonal antibody directed against the human tumor-associated antigen GD2, with potential antineoplastic activity. Upon vaccination, naxitamab stimulates antibody-dependent cell-mediated cytotoxicity (ADCC) against GD2-expressing tumor cells. GD2, a disialoganglioside with expression in normal tissues restricted primarily to the cerebellum and peripheral nerves, is commonly expressed at high levels on tumors of neuroectodermal origins such as melanomas and neuroblastomas. Compared to the murine monoclonal antibody 3F8 (m3F8), the humanized form does not cause a human anti-mouse antibody (HAMA) response and shows enhanced ADCC activity.

**Synonyms:** - Anti-Gd2 IGG3 Monoclonal Antibody 3f8 Humanized - Danyelza - Hu3F8 - Humanized Anti-GD2 Antibody 3F8 - Humanized Monoclonal Antibody Hu3f8-IGG1 - NAXITAMAB - Naxitamab-gqgk